Cart (0 Items)
Your cart is currently empty.
View ProductsBrand | ProteoGenix |
---|---|
Product type | Elisa assay kits |
Size | 96T |
Product name | Utomilumab ELISA Kit |
---|---|
Delivery condition | Blue ice (+4°) |
Storage condition | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
Brand | ProteoGenix |
Size | 96T |
Reference | KPTX242 |
Note | For research use only. |
Sample type | Plasma, Serum |
Immunogen | Utomilumab |
The Utomilumab ELISA Kit is a highly sensitive and specific assay designed for the detection and quantification of Utomilumab, a novel therapeutic antibody targeting cancer cells. This kit is a valuable tool for researchers and clinicians alike, providing key insights into the structure, activity, and potential applications of this promising antibody.
Utomilumab is a fully humanized IgG1 monoclonal antibody that specifically binds to the immune checkpoint receptor 4-1BB (CD137). It is composed of two identical heavy chains and two identical light chains, each containing a variable and constant region. The variable region is responsible for binding to the 4-1BB receptor, while the constant region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
The crystal structure of Utomilumab has been determined, revealing its unique binding mechanism to the 4-1BB receptor. The antibody binds to a specific region of the receptor, inducing a conformational change that results in the activation of downstream signaling pathways. This activation leads to enhanced T cell proliferation and cytokine production, making Utomilumab a promising immunotherapy for cancer treatment.
The main activity of Utomilumab is its ability to activate the immune system and promote anti-tumor responses. By binding to 4-1BB, Utomilumab enhances the proliferation and function of T cells, which play a crucial role in fighting cancer cells. In addition, Utomilumab has been shown to induce the production of cytokines such as interferon-gamma and tumor necrosis factor-alpha, which further contribute to its anti-tumor effects.
Furthermore, Utomilumab has been found to synergize with other cancer therapies, such as chemotherapy and radiation, leading to improved outcomes in preclinical studies. This highlights the potential of Utomilumab as a combination therapy for cancer treatment.
The Utomilumab ELISA Kit is a valuable tool for researchers and clinicians studying the potential applications of this novel therapeutic antibody. The kit allows for the precise and sensitive measurement of Utomilumab levels in various biological samples, such as serum, plasma, and cell culture supernatants.
One potential application of the Utomilumab ELISA Kit is in the monitoring of Utomilumab levels in patients undergoing treatment with this antibody. By measuring the levels of Utomilumab over time, clinicians can assess the efficacy of the treatment and make necessary adjustments to optimize patient outcomes.
In addition, the Utomilumab ELISA Kit can also be used in preclinical studies to evaluate the pharmacokinetics and pharmacodynamics of Utomilumab. This information is crucial for the development and optimization of dosing regimens for clinical trials.
The Utomilumab ELISA Kit is a powerful tool for studying the structure, activity, and potential applications of this promising therapeutic antibody. Its high sensitivity and specificity make it an ideal choice for researchers and clinicians looking to gain a deeper understanding of Utomilumab and its potential for cancer treatment. As research on Utomilumab continues, the Utomilumab ELISA Kit will undoubtedly play a crucial role in advancing our knowledge and improving patient outcomes.
Send us a message from the form below
Reviews
There are no reviews yet.